These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7577844)

  • 1. Molecular surface comparison. 2. Similarity of electrostatic vector fields in drug design.
    Blaney FE; Edge C; Phippen RW
    J Mol Graph; 1995 Jun; 13(3):165-74, 194-7. PubMed ID: 7577844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron.
    Toral J; Hu W; Critchett D; Solomon AJ; Barrett JE; Sokol PT; Ziai MR
    J Pharm Pharmacol; 1995 Jul; 47(7):618-22. PubMed ID: 8568632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An initial three-component pharmacophore for specific serotonin-3 receptor ligands.
    Rizzi JP; Nagel AA; Rosen T; McLean S; Seeger T
    J Med Chem; 1990 Oct; 33(10):2721-5. PubMed ID: 2145434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
    Langlois A; Pascaud X; Junien JL; Dahl SG; Rivière PJ
    Eur J Pharmacol; 1996 Dec; 318(1):141-4. PubMed ID: 9007525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions.
    López-Rodriguez ML; Benhamú B; Morcillo MJ; Murcia M; Viso A; Campillo M; Pardob L
    Curr Top Med Chem; 2002 Jun; 2(6):625-41. PubMed ID: 12052197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
    J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bidirectional allosteric modulation of strychnine-sensitive glycine receptors by tropeines and 5-HT3 serotonin receptor ligands.
    Maksay G
    Neuropharmacology; 1998 Dec; 37(12):1633-41. PubMed ID: 9886686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
    Barnes JM; Barnes NM
    Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.
    Adrien J; Tissier MH; Lanfumey L; Haj-Dahmane S; Jolas T; Franc B; Hamon M
    Neuropharmacology; 1992 Jun; 31(6):519-29. PubMed ID: 1407392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
    Squires RF; Saederup E
    Neurochem Res; 1999 May; 24(5):659-67. PubMed ID: 10344595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists.
    Tateishi T; Nakura H; Watanabe M; Tanaka M; Kumai T; Kobayashi S
    Cancer Lett; 1996 Nov; 108(1):1-5. PubMed ID: 8950202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.
    Bromidge SM; Dabbs S; Davies S; Duckworth DM; Forbes IT; Jones GE; Jones J; King FD; Saunders DV; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Riley GJ; Trail B; Wood MD
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1863-6. PubMed ID: 10969986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat.
    Costall B; Domeney AM; Naylor RJ
    Neuroreport; 1990 Sep; 1(1):77-80. PubMed ID: 1966601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High content pharmacophores from molecular fields: a biologically relevant method for comparing and understanding ligands.
    Cheeseright TJ; Mackey MD; Scoffin RA
    Curr Comput Aided Drug Des; 2011 Sep; 7(3):190-205. PubMed ID: 21726191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?
    Nevins ME; Anthony EW
    J Pharmacol Exp Ther; 1994 Jan; 268(1):248-54. PubMed ID: 7905528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.
    Bhandari P; Andrews PL
    Eur J Pharmacol; 1991 Nov; 204(3):273-80. PubMed ID: 1663456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of tryptophan residue(s) in the specific binding of agonists/antagonists to 5-HT3 receptors in NG108-15 clonal cells.
    Miquel MC; Emerit MB; Gozlan H; Hamon M
    Biochem Pharmacol; 1991 Sep; 42(7):1453-61. PubMed ID: 1930269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular electrostatic potential as a factor of drug-receptor recognition.
    Dukhovich FS; Darkhovskii MB
    J Mol Recognit; 2003; 16(4):191-202. PubMed ID: 12898669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.